• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Abundant development opportunities in immuno-oncology

by chantal | Nov 17, 2025 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Full steam ahead with iSCIB1+

by alex | Sep 11, 2025 | iSCIB1+, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SCOPE’ing out iSCIB1+ in advanced melanoma

by alex | Aug 4, 2025 | iSCIB1+, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Successful SCOPE outcome and iSCIB1+ selection

by chantal | Jul 22, 2025 | iSCIB1+, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Cancer vaccine data due soon; Glymab developments too

by chantal | Jul 10, 2025 | GlyMab, iSCIB1+, Modi-1, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

H125 reaffirms funds are sufficient to deliver key data

by alex | Jan 30, 2025 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Result of General Meeting
  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook
  • Notice of General Meeting October 2026

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy